The persistence of an intact reading frame within the genome of most FRDA patients opens the way to treatment attempts that target FXN gene transcription and messenger RNA (mRNA) translation to increase endogenous frataxin levels and balance the complex metabolic consequences of frataxin deficiency [4]. The gene discussed is FXN; the disease is hyperinsulinemic hypoglycemia, familial, 4.